| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19FN2O3 |
| Molecular Weight | 342.3642 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N[C@@H]1CN(C(=O)C1)C2=CC=C(OCC3=CC=CC(F)=C3)C=C2
InChI
InChIKey=VMAVCCUQTALHOB-INIZCTEOSA-N
InChI=1S/C19H19FN2O3/c1-13(23)21-16-10-19(24)22(11-16)17-5-7-18(8-6-17)25-12-14-3-2-4-15(20)9-14/h2-9,16H,10-12H2,1H3,(H,21,23)/t16-/m0/s1
| Molecular Formula | C19H19FN2O3 |
| Molecular Weight | 342.3642 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sembragiline is a potent, selective, long-acting, and reversible monoamine oxidase B (MAO-B) inhibitor developed as a potential treatment for Alzheimer's disease (AD). Sembragiline was involved in phase II clinical trial to evaluate its the safety, tolerability, and efficacy in patients with moderate AD. In addition, the drug was studied for smoking cessation, however, it failed to demonstrate efficacy during a phase II proof-of-concept trial.
